
MOLOGNI LUCA
- U08, Piano: 4, Stanza: LABORATORIO 4.10
- U08, Piano: 4, Stanza: 4043
Pubblicazioni
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante Varillas, S. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. PLOS ONE, 20(1) [10.1371/journal.pone.0308747]. Dettaglio
Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Dettaglio
Villa, M., Malighetti, F., De, S., Villa, A., Cordani, N., Aroldi, A., et al. (2025). Comprehensive analysis of mutational processes across 20 000 adult and pediatric tumors. NUCLEIC ACIDS RESEARCH, 53(13 (22 July 2025)) [10.1093/nar/gkaf648]. Dettaglio
Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio